一般来说, 无症状传染的几率不大; 因为感染性和病毒体内载量直接相关. 也就是说, the viral load is not
一般来说，无症状传染的几率不大， 因为感染性和病毒体内载量直接相关. 也就是说, the viral load is not enough to reach an infectious dose. 调节好自身状况，多休息多饮水，你身体健康没有underlying diseases, 就算中招也就如同感冒，别自己吓自己。(就目前Omicron来看，COVID-19 will join the 4 other coronaviruses we deal with that cause the common cold, upper respiratory infections, RSV, etc. It will become a pediatric disease mainly affecting young children with no immunity).
The viral load is a measure of how bright the fire is burning in an individual, whereas the infectious dose is the spark that gets that fire going.
Objectives/hypothesis: To determine the effect of povidone-iodine (PVP-I) nasal sprays on nasopharyngeal (NP) viral load as assessed by cycle threshold (Ct) on quantitative polymerase chain reaction (qPCR) of SARS-CoV-2 in outpatients.
Study design: Three arm, triple blinded, randomized, placebo-controlled clinical trial.
Methods: Participants were randomized within 5 days of testing positive for COVID-19 to receive nasal sprays containing placebo (0.9% saline), 0.5% PVP-I, or 2.0% PVP-I. NP swabs for qPCR analysis were taken at baseline, 1-hour post-PVP-I spray (two sprays/nostril), and 3 days post-PVP-I spray (20 sprays/nostril). Symptom and adverse event questionnaires were completed at baseline, day 3, and day 5. University of Pennsylvania Smell Identification Tests (UPSIT) were completed at baseline and day 30.
Results: Mean Ct values increased over time in all groups, indicating declining viral loads, with no statistically significant difference noted in the rate of change between placebo and PVP-I groups. The 2.0% PVP-I group showed statistically significant improvement in all symptom categories; however, it also reported a high rate of nasal burning. Olfaction via UPSIT showed improvement by at least one category in all groups. There were no hospitalizations or mortalities within 30 days of study enrollment.
Conclusions: Saline and low concentration PVP-I nasal sprays are well tolerated. Similar reductions in SARS-CoV-2 NP viral load were seen over time in all groups. All treatment groups showed improvement in olfaction over 30 days. These data suggest that dilute versions of PVP-I nasal spray are safe for topical use in the nasal cavity, but that PVP-I does not demonstrate virucidal activity in COVID-19 positive outpatients.
我上个星期三和他一起工作两小时，都是同事又是室外工作，我忘了自己是否戴口罩了。
我星期四，星期五在客户那里做检查都是阴性。
刚才同事打电话说他昨晚开始发低烧，今天下雪也没去测。
我无所谓，但是
不想和怕死的结实说，估计说了她又得求着让我住旅馆了。
请问懂行的哥们儿姐妹儿：
我和同事上星期三接触过，现在也没症状，又测过是阴性，应该没事儿吧？
夫妻同房不同床。
一般来说，无症状传染的几率不大， 因为感染性和病毒体内载量直接相关. 也就是说, the viral load is not enough to reach an infectious dose. 调节好自身状况，多休息多饮水，你身体健康没有underlying diseases, 就算中招也就如同感冒，别自己吓自己。(就目前Omicron来看，COVID-19 will join the 4 other coronaviruses we deal with that cause the common cold, upper respiratory infections, RSV, etc. It will become a pediatric disease mainly affecting young children with no immunity).
The viral load is a measure of how bright the fire is burning in an individual, whereas the infectious dose is the spark that gets that fire going.
欲哥看看这篇文章：https://www.bmj.com/content/371/bmj.m4695
我妹妹每年都爱得流感，说她的流感症状比这个更难受得多。
https://www.wenxuecity.com/news/2022/01/24/socialnews-216480.html
https://pubmed.ncbi.nlm.nih.gov/34724213/
The Effect of Povidone-Iodine Nasal Spray on Nasopharyngeal SARS-CoV-2 Viral Load: A Randomized Control Trial
AbstractObjectives/hypothesis: To determine the effect of povidone-iodine (PVP-I) nasal sprays on nasopharyngeal (NP) viral load as assessed by cycle threshold (Ct) on quantitative polymerase chain reaction (qPCR) of SARS-CoV-2 in outpatients.
Study design: Three arm, triple blinded, randomized, placebo-controlled clinical trial.
Methods: Participants were randomized within 5 days of testing positive for COVID-19 to receive nasal sprays containing placebo (0.9% saline), 0.5% PVP-I, or 2.0% PVP-I. NP swabs for qPCR analysis were taken at baseline, 1-hour post-PVP-I spray (two sprays/nostril), and 3 days post-PVP-I spray (20 sprays/nostril). Symptom and adverse event questionnaires were completed at baseline, day 3, and day 5. University of Pennsylvania Smell Identification Tests (UPSIT) were completed at baseline and day 30.
Results: Mean Ct values increased over time in all groups, indicating declining viral loads, with no statistically significant difference noted in the rate of change between placebo and PVP-I groups. The 2.0% PVP-I group showed statistically significant improvement in all symptom categories; however, it also reported a high rate of nasal burning. Olfaction via UPSIT showed improvement by at least one category in all groups. There were no hospitalizations or mortalities within 30 days of study enrollment.
Conclusions: Saline and low concentration PVP-I nasal sprays are well tolerated. Similar reductions in SARS-CoV-2 NP viral load were seen over time in all groups. All treatment groups showed improvement in olfaction over 30 days. These data suggest that dilute versions of PVP-I nasal spray are safe for topical use in the nasal cavity, but that PVP-I does not demonstrate virucidal activity in COVID-19 positive outpatients.
Level of evidence: II Laryngoscope, 2021.